Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$34.37
-0.63 (-1.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $159.1M · quality 82.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.9B
P/E
54.6x
↑EV/EBITDA
24.8x
↑ROE
7.7%
↑Gross Margin
39.5%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.2%
FCF CAGR
+18.8%
FCF margin
13.6%
FCF / Net income
1.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.42B · net income $125.4M · FCF $194.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.42B | $1.42B | $1.54B | $1.63B | $1.57B |
| Net Income | $125.4M | $125.4M | $80.3M | $138.4M | $127.3M |
| EBITDA | $270.3M | $270.3M | $262.6M | $300.1M | $214.4M |
| EPS | 0.62 | 0.62 | 0.40 | 0.69 | 0.64 |
| Gross Margin | 39.5% | 39.5% | 40.1% | 44.6% | 57.2% |
| Operating Margin | 14.3% | 14.3% | 10.6% | 13.3% | 9.2% |
| Net Margin | 8.8% | 8.8% | 5.2% | 8.5% | 8.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.32 | 0.37 | 0.23 |
| Current Ratio | 1.90 | 1.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $194.2M | $194.2M | $159.1M | $152.0M | $115.9M |
| Returns | |||||
| ROE | 7.7% | 7.7% | 5.2% | 8.7% | 8.5% |
| Valuation | |||||
| P/E | 54.56 | 54.56 | 32.25 | 30.13 | 31.00 |
| EV/EBITDA | 24.84 | 24.84 | 9.06 | 12.98 | 16.58 |
| P/B | 4.27 | 4.27 | 1.69 | 2.63 | 2.63 |
| Growth & Yield | |||||
| Revenue Growth | -7.4% | -7.4% | -5.4% | 3.7% | — |
| EPS Growth | 55.0% | 55.0% | -42.0% | 7.8% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
70.1%
EPS terminal req.
$3.05
Spread vs growth
-15.1%
5Y implied EPS CAGR
42.9%
EPS terminal req.
$3.69
Spread vs growth
12.1%
10Y implied EPS CAGR
25.4%
EPS terminal req.
$5.94
Spread vs growth
29.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+151.4%
Start / end P/E
34.3x → 55.4x
EPS bridge
0.40 → 0.62
Residual
+34.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.